Tag: 시장 접근
The Scary Future of Rare Disease Management
In a world of rising healthcare costs, the greatest nightmare for payers is reimbursing drug interventions that do not meaningfully benefit their covered lives. Rare disease therapies, often viewed as attractive areas for pharmaceutical & biotech manufacturers, represent some of the most expensive interventions available today given inherently limited competition. Yet, as more manufacturers enter … Continued
Bio-Europe Digital
AMCP Nexus 2021
Succeeding in Value Communication: Introduction
Drawn from the experiences of the BaseCase Consulting Team, this is the introduction to ‘Succeeding in Value Communication’. This series of blog articles examines the key success factors in creating customer engagement tools that effectively communicate the clinical value and economic benefits of pharmaceuticals, medical devices, and diagnostic tests. How do you communicate the value … Continued
Innovations in Value Communication: Optimizing Payer Engagement at the Local Level
9월 14, 2021 – 11:00 am ET Securing reimbursement from national payers is critical to your product’s commercial success. However, payers at the local and regional levels continue to get more authority to manage their own budgets. This makes engaging with payers and designing an effective strategy for value communication difficult as the concept of … Continued
What is BaseCase?
Developing interactive and easy-to-use stakeholder engagement content market access, medical affairs, and sales field teams is a time-consuming, expensive, and often decentralized process. BaseCase is “no-code” platform that enables you to visualize large complex datasets and economic models, which demonstrates the value of products to key decision-makers.
Three Pathways have emerged in Innovative Access Agreements
The days of simply determining the market demand for a new drug as a function of price and choosing the revenue or profit optimizing point are gone. In our new environment, an explicit rationale, the “value-based price” has become a prerequisite for enabling conversation with payers while policy-makers seem poised to limit the pricing corridors … Continued
Outcomes Based Agreements
The days of simply determining the market demand for a new drug as a function of price and choosing the revenue or profit optimizing point are gone. In our new environment, an explicit rationale, the “value-based price” has become a prerequisite for enabling conversation with payers while policy-makers seem poised to limit the pricing corridors … Continued
Stakeholder perspectives: current and potential benefits
Amongst the real world data sources in Europe, the French Healthcare database SNDS is the largest and potentially the most comprehensive healthcare data resource, covering ~65 million lives, more than 99% of the French population and about 10% of Europe. Watch this short video by Nadia Quignot, Director, Decision Analytics & Real World Evidence at … Continued
